DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the VAISHALI PHARMA LIMITED (VAISHALI) share price today?

VAISHALI PHARMA LIMITED (VAISHALI) is trading at ₹7.84 on the NSE, down 0.51% on the day. Source: DocStoX.

What is the PE ratio of VAISHALI PHARMA LIMITED?

VAISHALI PHARMA LIMITED has a price-to-earnings (PE) ratio of 24.5 in the Healthcare sector.

What is the market capitalisation of VAISHALI PHARMA LIMITED?

VAISHALI PHARMA LIMITED has a market capitalisation of approximately ₹0 crore.

VAISHALI PHARMA LIMITED

VAISHALI·NSE·Healthcare

₹7.84▼ -0.04 (-0.51%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹7.72

₹8.18

52W₹5

₹1435%

Open

₹7.88

High

₹8.18

Low

₹7.72

Prev Close

₹7.88

Volume

23.5K

VWAP

₹7.83

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

24.50Fair

P/B Ratio

1.36

EPS

₹0.32

Book Value

₹5.30

ROE

6.02%Weak

ROCE

4.02%Weak

Dividend Yield

0.00%

Debt / Equity

0.28Low

Face Value

₹2.00

52W High

₹13.59

52W Low

₹4.75

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹5

▼ 33.5%downside

Trading at ₹8 — 33% above our estimate

BearFair valueBull

₹4₹5₹6

/100

Business quality — Watch the fundamentals

Growth 50Profitability 7Efficiency 0Valuation 75

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (6%)

Strengths

Low debt relative to equity

Risks

Weak returns on equity (6%)
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

6% ROE fading to 12% over ~3 yrs, on ₹5 book

₹5

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹6

Analyst target

No analyst coverage

—

Blended fair value₹5

What the numbers say

Investment thesis

Bull case

Low debt relative to equity

Bear case

Weak returns on equity (6%)
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

24.5Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

6.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

4.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.28Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

1.36

EPS

₹0.32

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Reasonable

P/E 24.5×

Growth

N/A

No history

Profitability

Modest

6.0% ROE

Financial health

Rock solid

D/E 0.28

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹1.84L Cr

Trades102

VWAP₹7.83

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Cons

Promoter holding is low: 31.6%
Earnings include an other income of Rs.3.84 Cr.
Company has high debtors of 170 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

32%

Promoter

Promoters

31.6%0.00

Public

62.3%-0.43

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

6.1%

Total shareholders

26,534-1,218 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter31.61%

Public62.32%

Others6.07%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1989, Vaishali Pharma Ltd does marketing of pharmaceutical products including active pharmaceutical ingredients[1]